Articles tagged with Prostate Cancer
The CNRCS has awarded three students for their work on prostate cancer, including Jayantha Tennakoon, who aims to identify molecules that provoke cancer cell growth. Undergraduate Hannah Do is maintaining a drug library to isolate new therapeutic targets for advanced prostate cancer. Eylem Aydogdu became the first Ph.D. graduate at the...
A survey of primary care doctors found that many resist stopping routine PSA testing due to patient expectations and malpractice concerns. Researchers are working on a decision-making tool to help doctors make informed choices about prostate cancer screening.
Researchers found that statin users had less prostate growth compared to non-users, regardless of whether they took dutasteride or a placebo. The effect was relatively small and tapered off after two years.
The USPSTF recommends against PSA-based screening for all men regardless of age, citing significant harms associated with the test. The Task Force concludes that the benefits of screening do not outweigh the risks, which include unnecessary treatments and life-long adverse effects.
Researchers have identified a unique molecular subtype of prostate cancer associated with mutations in the SPOP gene, accounting for up to 15% of all cases. The study reveals that these mutations may lead to an accumulation of proteins driving cancer growth.
A study presented at the American Urological Association Annual Meeting found that early stage prostate cancer treatment can alleviate lower urinary tract symptoms (LUTS) in a subgroup of men. Radical prostatectomy surgery was shown to improve urinary function, while radiation therapy and brachytherapy had less favorable effects.
A new UCLA study finds that nerve-sparing surgical techniques and experienced surgeons can improve erectile function after prostate cancer surgery. Surgeons with at least 1,000 cases under their belt and those who actively seek improvement have better outcomes.
A phase II clinical trial found that abiraterone acetate, a hormone-depleting drug, can nearly eliminate or eliminate tumors in patients with aggressive cancers isolated to the prostate gland. The study showed promising results, encouraging further research into new treatments for high-risk prostate cancer.
Researchers will investigate Cu-64, a biomolecule that selectively seeks out a prostate tumor biomarker, to stage prostate cancers and detect recurrent disease accurately. The new technique involves PET scans and could significantly reduce the number of confirmation biopsies.
A new study found that patients undergoing radical prostatectomy surgery in accredited teaching hospitals with residency programs experienced fewer complications than those in non-teaching institutions. Those with private insurance also had better outcomes. The study suggests that specialized care and peer-review processes may contribu...
Research at Henry Ford Hospital found that higher hospital volume and surgeon volume both lead to better surgical results, but hospital volume matters more for older, sicker patients. The study analyzed data from 19,225 Medicare patients with prostate cancer who underwent radical prostatectomy between 1995 and 2005.
A recent study found racial disparities in the results of radical prostatectomy for African American patients compared to white patients. The researchers identified five areas where African Americans had poorer outcomes, including blood transfusions, complications during and after surgery, and prolonged hospital stays.
Researchers identify DNA methylation profiles as potential biomarkers for detecting prostate cancer months earlier than current methods. The discovery also predicts recurrence risk and identifies genes that can be targeted with new drugs.
A new technique has been reported in the American Journal of Pathology that uses genetic abnormalities to predict prostate cancer relapse. The study found that copy number variations (CNVs) in both cancerous and non-cancerous tissues can accurately forecast recurrence, allowing for more targeted treatment approaches.
Research suggests that PSA screening can reduce deaths from prostate cancer in younger, healthy men. The benefit of screening is particularly significant in men with risk factors such as black ancestry or positive family history. Screening may be discontinued for elderly men with multiple comorbidities and limited life expectancy.
Researchers discovered a population of low-PSA prostate cancer stem cells that are resistant to hormone therapy and chemotherapy. These cells can differentiate into other cancer cell types and have long-term tumor-propagating capacity.
A compound isolated from honeybee hive propolis has been found to slow the growth of prostate cancer cells and tumors in mice by shutting down their system for detecting sources of nutrition. The compound CAPE arrests early-stage prostate cancer by suppressing proteins involved in cell proliferation, offering a promising co-treatment a...
A literature review highlights the need for a tailored approach to improving quality of life in subpopulations, including African Americans, Latin Americans, Asians, and men who have sex with men. The authors emphasize the importance of considering demographic, socioeconomic, and sexual preference factors in treatment decision-making.
A new diagnostic tool using gold nanoparticles can determine the aggressiveness of prostate cancer, providing doctors with more accurate information to treat patients. The test has been validated in human tissue samples and could lead to more treatment options if clinical trials begin in two to three years.
The study found that robot-assisted radical prostatectomy (RARP) resulted in superior outcomes compared to open radical prostatectomy (ORP), including reduced need for blood transfusions and complications during or after surgery. RARP patients were also less likely to have prolonged hospital stays.
A study by Long Island University researchers found that carvacrol, an oregano constituent, induces apoptosis in prostate cancer cells. This compound may represent a promising anti-cancer agent with reduced risk of severe side effects due to its common use as food seasoning.
A study confirms that prostate cancer screening is widely ignored in men aged 75 or older, defying 2008 guidelines. Nearly half of men in this age group continue to receive screenings, highlighting the need for selective screening.
A recent study compared the adverse effects of intensity-modulated radiation therapy (IMRT), proton therapy, and conformal radiation therapy in treating localized prostate cancer. The results showed that IMRT was associated with fewer gastrointestinal adverse effects and hip fractures but more erectile dysfunction, while proton therapy...
A study published in JAMA found Intensity Modulated Radiation Therapy (IMRT) to be more effective in reducing certain side effects and preventing cancer recurrence compared to conventional conformal radiation therapy (CRT). IMRT was also comparable to proton therapy, a newer technique.
Researchers study the origins of HIV/AIDS, revealing that SIV replication in human tissues is crucial to viral efficiency. In contrast, a new study finds that autoantibodies against citrullinated proteins contribute to bone loss in rheumatoid arthritis patients.
A study shows a botanical formula significantly suppresses tumor growth in aggressive human prostate cancer cells, demonstrating its safety and effectiveness. The formula inhibits several genes related to cancer proliferation and increases the expression of cancer-fighting genes.
A new study suggests that policies to reduce healthcare costs may compromise quality care by depriving patients of needed services. The research found that regions with high rates of inappropriate imaging also had high rates of appropriate imaging, highlighting the need for a more nuanced approach.
Researchers have identified two inherited-genetic deletions in the human genome that significantly increase a man's risk of developing aggressive prostate cancer. One deletion affects a known gene, while the other is found in non-coding DNA and regulates a cascade of genes.
A new drug developed by Northwestern Medicine scientists has prevented human prostate cancer cells from spreading to other tissues. The drug inhibits movement of the cells and prevents metastasis without causing harm to normal cells or tissues.
A phase II study found metformin reduced fasting glucose, insulin levels and body mass index in men with prostate cancer. The medication also appeared to slow the growth rate of prostate cancer in a proportion of men.
A recent study has found that low oxygen levels in tumors can predict cancer recurrence in men with intermediate-risk prostate cancer. The research, led by radiation oncologists at the Princess Margaret Hospital, suggests that these patients are more likely to develop cancer recurrence within a few years of completing treatment.
Galeterone, a small-molecule oral drug, demonstrated limited side effects and reduced prostate-specific antigen expression in patients with castration-resistant prostate cancer. The drug's triple mechanism of action showed promise in blocking the growth of prostate cancer cells.
A Phase 1 study demonstrated galeterone's tolerability and efficacy in patients with castration-resistant prostate cancer, with minimal toxicities reported. The study showed significant reductions in tumor size and prostate-specific antigen levels in nearly half of the patients evaluated.
Researchers have discovered a new mechanism of prostate cancer cell metabolism by identifying the PFKFB4 gene, which is vital for tumor growth and antioxidant production. The study found that depletion of this gene in laboratory models inhibited tumor growth, suggesting potential targeted therapies.
A recent study conducted at Marshall University investigated the effects of cadmium on the prostate, revealing molecular mechanisms that induce carcinogenesis. The research, published in PLOS ONE, may lead to new therapies for prostate cancer.
Scientists at UC San Diego School of Medicine developed a new strategy for faster anticancer drug discovery by analyzing the genetic pathway of disease. They identified Peruvoside, a cardiac glycoside, as a potential treatment for prostate cancer with minimal side effects.
A new analysis suggests that circumcision before a male's first sexual intercourse may reduce the risk of developing prostate cancer. Men who were circumcised had a 15% lower risk of developing prostate cancer compared to uncircumcised men, with reduced risks for both less aggressive and more aggressive cancers.
Research at Yale University reveals that prostate cancer treatment is often not necessary for older men with short life expectancy. The study found that cancer treatment became more common among men with moderate-risk tumors and shorter life expectancies, despite being unlikely to benefit from it.
A study employing mouse models and genomic analysis of human tumors identified the Smad4 gene as a driver in bone metastasis, while 14 other genes were found to be associated with human prostate cancer prognosis. Telomerase activation confers new strengths on tumors, enabling them to progress and acquire deadly characteristics.
Four new drugs offer innovative methods of action against prostate cancer, including bone protective agents, hormone treatments and immunotherapy. These advancements could extend survival prognosis and potentially turn prostate cancer into a chronic disease.
Researchers at Thomas Jefferson University found that curcumin suppresses nuclear receptor activators, which can bypass androgen deprivation therapy. Curcumin also reduced cell number and inhibited survival in prostate cancer cells, with similar results seen in mice studies.
Researchers found a significant correlation between coronary artery disease and prostate cancer in a large study, suggesting that heart disease may be a risk factor for the malignancy. Lifestyle changes such as weight loss, exercise, and a healthy diet may help combat both conditions.
Researchers at LSU Health Sciences Center have identified a new protein called ARD1 that plays a critical role in the development and growth of prostate cancer. Inactivating this protein completely suppresses cancer growth, making it a potential target for new treatments.
A multicenter study found two biomarkers in urine to correlate with aggressive prostate cancer among men on active surveillance. The markers, PCA3 and TMPRSS2-ERG, may lead to a non-invasive test to complement biopsy for predicting disease aggressiveness and progression.
A study by UCSF researchers found that vigorous exercise is linked to increased expression of genes thought to prevent cancer progression. The study identified nearly 200 genes in healthy prostate tissue that are more active among men who exercised vigorously for at least three hours a week.
Research from the 2012 Genitourinary Cancers Symposium highlights promising new therapies for prostate cancer, including vigorous exercise and targeted drugs that improve survival rates. The studies also compare existing treatments, such as radiation therapy and hormone therapy, to determine their effectiveness.
The phase III clinical trial shows that men treated with MDV3100 had a median survival of 18.4 months compared to 13.6 months for those receiving placebo, resulting in a 37% reduction in mortality risk. This breakthrough treatment tackles drug-resistant prostate cancer, providing new hope for patients.
A new study published in Radiology found that preoperative MRI helps surgeons make informed decisions about nerve-sparing procedures for men with prostate cancer. The imaging modality changed the surgical plan in 28% of patients, without compromising oncologic outcomes.
A commonly used medication for enlarged prostates may also slow the progression of early-stage prostate cancer, according to a new study. The treatment, dutasteride, was found to delay disease progression and reduce anxiety related to the disease in patients undergoing active surveillance.
A three-year clinical trial shows dutasteride delays prostate cancer disease progression by 38% compared to placebo, while also reducing anxiety. The study suggests a viable treatment option for men with low-risk disease, offering a safer alternative to aggressive local treatment.
A Kansas State University researcher is studying foods and dietary supplements that may reduce the risk of prostate cancer. Finasteride and dutasteride drugs, which lower testosterone levels, have shown promise in reducing prostate cancer incidence but may lead to worse outcomes for those who develop the disease.
Researchers at Wayne State University are investigating the role of c-kit in bone metastasis of prostate cancer. They aim to understand how factors from the bone stimulate the production of c-kit and its ligand in prostate cancer cells, facilitating their growth and survival.
Researchers have identified a rare genetic mutation linked to a significantly higher risk of developing prostate cancer, particularly in men with a family history of early-onset disease. The mutation, called HOXB13, is associated with a 10-20 times higher risk of developing prostate cancer.
Researchers have identified a rare, inherited mutation linked to a significantly higher risk of developing prostate cancer. The mutation was found in 10-20 times more men who inherited it compared to the general population. Further studies may lead to genetic testing for inherited prostate cancer.
New research confirms that annual prostate cancer screening does not reduce deaths from the disease, even among men in their 50s and 60s with underlying health conditions. The study found that six years of aggressive screening led to more diagnoses of tumors but not fewer deaths.
Men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial had no evidence of a mortality benefit from annual PSA testing compared to usual care. The study found a higher percentage of deaths from other causes among prostate cancer patients diagnosed with PSA screening, indicating over-diagnosis.
A study found that biopsy referral rates for men with high PSA levels remained stable despite recent recommendations to lower the threshold. Biopsies became slightly less common over time, likely due to growing awareness of overdiagnosis and overtreatment.
A new molecular imaging probe using ghrelin exploits the hunger hormone's unique consumption pattern by malignant prostate cancer cells. The test showed the signal was almost 5 times stronger in malignant cancer cells than in normal or benign cells.
An independent panel recommends closely monitoring men with localized, low-risk prostate cancer to delay treatment until disease progression. However, standardizing definitions and conducting additional studies are needed to clarify management strategies and optimize patient outcomes.
Researchers suggest combining PSA testing with factors like prostate size, weight, and family history to identify aggressive cancers and avoid unnecessary biopsies. This approach could potentially save up to a quarter of men from undergoing biopsies and related risks.